Biomaterial control of therapeutic stem cells

408 Pages·2019·9.839 MB·English

by  Higuchi, Akon

Biomaterial Control of Therapeutic Stem Cells
1
0
0
P
F
0-
9
6
2
1
0
8
8
7
1
8
7
9
9/
3
0
1
0.
1
oi:
d
g |
or
c.
s
s.r
b
u
p
s://
p
htt
n
o
9
1
0
2
y
ar
u
br
e
F
8
1
n
o
d
e
h
s
bli
u
P
View Online
Biomaterials Science Series
Editor-in-chief:
Julian Jones, Imperial College London, UK
1
0
0
P
F Series editors:
0-
69 Cole DeForest, University of Washington, USA
2
01 Changyou Gao, Zhejiang University, China
8
8
7
1
78 Titles in the Series:
9
9/ 1: Stimuli-responsive Drug Delivery Systems
3
0
1 2: Biodegradable Thermogels
0.
oi:1 3: Biofabrication and 3D Tissue Modeling
g | d 4: Biomaterial Control of Therapeutic Stem Cells
or
c.
s
s.r
b
u
p
s://
p
htt
n
o
9
1
0
2
y
ar
u
br
e
F
8
1
n
o
d
e
h
s
bli
u
P
How to obtain future titles on publication:
Astandingorderplanisavailableforthisseries.Astandingorderwillbring
delivery of each new volume immediately on publication.
For further information please contact:
BookSalesDepartment,RoyalSocietyofChemistry,ThomasGrahamHouse,
Science Park, Milton Road, Cambridge, CB4 0WF, UK
Telephone: þ44 (0)1223 420066, Fax: þ44 (0)1223 420247
Email: [email protected]
Visit our website at www.rsc.org/books
View Online
Biomaterial Control of
Therapeutic Stem Cells
1
0
0
P
F
0-
9
6
2
1
0
8 By
8
7
1
8
7
9/9 Akon Higuchi
3
0 National Central University, Taiwan
1
10. Email: [email protected]
oi:
d
g |
or
c.
s
s.r
b
u
p
s://
p
htt
n
o
9
1
0
2
y
ar
u
br
e
F
8
1
n
o
d
e
h
s
bli
u
P
View Online
1
0
0
P
F
0-
9
6
2
1
0
8
8
7
1
8
97 BiomaterialsScienceSeriesNo.4
9/
3
0
0.1 PrintISBN:978-1-78801-207-2
oi:1 PDFISBN:978-1-78801-269-0
d EPUBISBN:978-1-78801-763-3
g | PrintISSN:2397-1401
or
c. ElectronicISSN:2397-141X
s
s.r
b
u AcataloguerecordforthisbookisavailablefromtheBritishLibrary
p
s://
http rAkonHiguchi2019
n
o
9 Allrightsreserved
1
0
2
ary Apartfromfairdealingforthepurposesofresearchfornon-commercialpurposesorfor
bru privatestudy,criticismorreview,aspermittedundertheCopyright,DesignsandPatents
Fe Act1988andtheCopyrightandRelatedRightsRegulations2003,thispublicationmaynot
18 bereproduced,storedortransmitted,inanyformorbyanymeans,withouttheprior
on permissioninwritingofTheRoyalSocietyofChemistryorthecopyrightowner,orinthe
ed caseofreproductioninaccordancewiththetermsoflicencesissuedbytheCopyright
h
s LicensingAgencyintheUK,orinaccordancewiththetermsofthelicencesissuedby
ubli theappropriateReproductionRightsOrganizationoutsidetheUK.Enquiriesconcerning
P
reproductionoutsidethetermsstatedhereshouldbesenttoTheRoyalSocietyof
Chemistryattheaddressprintedonthispage.
Whilstthismaterialhasbeenproducedwithallduecare,TheRoyalSocietyofChemistry
cannotbeheldresponsibleorliableforitsaccuracyandcompleteness,norforany
consequencesarisingfromanyerrorsortheuseoftheinformationcontainedinthis
publication.Thepublicationofadvertisementsdoesnotconstituteanyendorsementby
TheRoyalSocietyofChemistryorAuthorsofanyproductsadvertised.Theviewsand
opinionsadvancedbycontributorsdonotnecessarilyreflectthoseofTheRoyalSocietyof
Chemistrywhichshallnotbeliableforanyresultinglossordamagearisingasaresultof
relianceuponthismaterial.
TheRoyalSocietyofChemistryisacharity,registeredinEnglandandWales,
Number207890,andacompanyincorporatedinEnglandbyRoyalCharter
(RegisteredNo.RC000524),registeredoffice:BurlingtonHouse,Piccadilly,
LondonW1J0BA,UK,Telephone:þ44(0)2074378656.
Forfurtherinformationseeourwebsiteatwww.rsc.org
PrintedintheUnitedKingdombyCPIGroup(UK)Ltd,Croydon,CR04YY,UK
5
0
0
P
F
0-
69 Preface
2
1
0
8
8
7
1
8
7
9
9/
3
0
1
0.
1
oi: This book, Biomaterial Control of Therapeutic Stem Cells, describes bio-
d
g | materials for culture and differentiation of human embryonic stem (hES)
or cellsandhumaninducedpluripotentstem(hiPS)cellsaswellasbiomaterials
c.
s.rs used in clinical trials of stem cell therapy. Human pluripotent stem (hPS)
ub cells, which cover bothhES cells and hiPScells,show promisefordrug dis-
p
s:// covery and regenerative medicine applications. These stem cells cannot be
p
htt culturedonconventionaltissuecultureplatesingeneralbutonbiomaterials
on thathavespecificinteractionswiththehPScells.Differentiationisregulated
9
1 bythebiologicalandphysicalcuesconferredbythebiomaterials.Thisbook
0
2
y provides a systematic discussion of these topics, bridging the gap between
ar
u fundamental biomaterials research of stem cells and their use in clinical
br
Fe trials.Thebookismainlywrittenformaterialscientists,whetherornotthey
8
1 haveanyknowledgeofstemcells,butwhoareeagertobegintheirresearch
n
d o intostemcellcultureanddifferentiation.Themotivationtowritethisbook
e
h originates with my research history. I started my research in the field of
s
bli physical chemistry (i.e., transport of small molecules through polymeric
u
P
membranes) when I was an undergraduate student under the guidance of
ProfessorToruKawaiattheTokyoInstituteofTechnology,Japan.Membrane
research was a hot topic in the 1970s, but the research boom in membrane
sciencequicklydiminishedafter1970. Ialwayswantedtoworkonsuchhot
topics but I had no knowledge of organic chemistry or biochemistry at that
time, which prevented me from continuing my bioengineering research.
Fortunately,Ilearnedaboutthesimplechemicalreactionsofpolymerization
andsurfacemodificationofmaterialsduringmyworkexperienceataprivate
chemical company(Asahi KaseiCorporation)in1985,and acknowledge the
help and support of my colleague, Mr Kubota Noboru, and my supervisor,
MrTakayukiYokoyama,duringmytimethere.Ithenbeganmyownresearch
atMeijiUniversity,Japan.Istartedmyresearchtargetingthebio-fieldusing
BiomaterialsScienceSeriesNo.4
BiomaterialControlofTherapeuticStemCells
ByAkonHiguchi
rAkonHiguchi2019
PublishedbytheRoyalSocietyofChemistry,www.rsc.org
v
View Online
vi Preface
materials such as biosensor preparation, but wanted to move on from the
area of biosensor research. When I set up my own laboratory at Seikei
University, Tokyo, in 1993, Dr Seiji Manabe kindly supported me and we
worked together on transport phenomena through virus removal filters
05 (Planova).Iwasthenfortunatetolearnthetechniquesofcancercellculture
0
FP fromDrManabe’slaboratory.From1990to2010,Iworkedonthecultivation
90- of hematopoietic stem cells and adipose-derived stem cells on several bio-
6
12 materials.Severaldoctorsfromavarietyofclinicskindlysuppliedperipheral
0
88 blood and umbilical cord blood, including Dr Mitsuo Hattori from Seikei
7
81 University. Collaboration with doctors is very important to progress in this
7
9/9 field. Myself and the students in my laboratory isolated stem cells from
3
0 peripheral blood, umbilical cord blood and fat tissues and cultured these
1
10. stem cells on home-made biomaterials. I moved from Seikei University in
doi: Tokyo,Japan,totheNationalCentralUniversity,Taiwan,in2007.Since2010,
g | my laboratory has been more focused on hES cell and hiPS cell culture and
or
c. differentiation,whichareculturedonseveralbiomaterials.Itischallenging
s
bs.r to control the differentiation fate of stem cells by regulating their micro-
u
ps://p eonfvbiiroomnmateernita,lssu.Hchowasevbeyrc,ownetbroellliienvgeothnalytwtheecpahnyrseigcaullaotrecthheemstiecmalpcerlolpfeartetieosf
n htt differentiation by cell culture biomaterial characteristics, which are micro-
o
9 environmentsofstemcells.Thisissueisalsosignificantintermsofhuman
1
20 society;ourperformanceandability,includingoursocialpositionandstatus,
y
ar couldbeimprovedbyourenvironment,whichisnotcontrolledsolelybyour
u
br heredity.Wethinkthattheroleofthestemcellmicroenvironment(stemcell
e
F
8 culture biomaterials) in deciding and regulating stem cell fate of differen-
1
n tiation is similar to that of the human fate in our society. Therefore, any
o
ed materialscientistswhoareinterestedtoprogresstheirresearchinthestem
h
blis cell field can gain fundamental knowledge as well as the current status of
Pu stemcellcultureanddifferentiation,andcurrenttrendsinstemcelltherapy
fromthisbook.Iamhappyforreaderstousethisbookasadictionary,which
includes fundamental data such as three germ layer gene and proteins,
extracellular matrices (ECMs)and ECM-derived oligopeptide, integrin bind-
ing for specific extracellular matrix, research examples of stem cell culture
using specific extracellular matrices, differentiation methods into specific
anddesiredlineageofthecells,andrecentclinicaltrialexamples,etc.
FinallyIwouldliketothanktheRoyalSocietyofChemistryforgivingmea
chance to write this book, especially Michelle Carey and Connor Sheppard.
I also thank my colleagues, Shang-Lin (Sophie) Chen, Dr Tzu-Cheng Sung,
ProfessorYungChang,ProfessorQing-DongLing,ProfessorAkihiroUmezawa,
otherfriendsandmyfamilymembers.Ialsothank AsahiKaseiCorporation,
Meiji University, Seikei University, National Central University, King Saud
University,Riken,NationalCenterforChildHealthandDevelopment,Ministry
ofEducation,Culture,Sports,Science,andTechnologyofJapan,andMinistry
ofScienceandTechnology,Taiwanforsupportingmyresearch.
Akon Higuchi
7
0
0
P
F
0-
69 Abbreviations
2
1
0
8
8
7
1
8
7
9
9/
3
0
1
0.
1
oi: 2D two-dimensional
g | d 3D three-dimensional
or ADS cell, ADSC adipose-derived stem cell
c.
s.rs AEtMA-Cl 2-(acryloyloxyethyl) trimethylammonium chloride
ub AFM atomic force microscopy
p
s:// AFP a-fetoprotein
p
htt Akt serine–threonine kinase
on ALP alkaline phosphatase
9
1 AMI acute myocardial infarction
0
2
y AMS cell amniotic membrane-derived stem cell
uar APMAAm aminopropylmethacrylamide
br
e ASGPR asialoglycoprotein receptor
F
18 BBB Basso, Beattie, Bresnahan
n
o BBS borate buffered saline
d
he BIO bromo-indirubin-30-oxime
s
bli BM bone marrow
u
P
BMN cell bone marrow mononuclear cell
BMS cell bone marrow-derived stem cell
BSA bovine serum albumin
CA cellulose acetate
CABG coronary artery bypass grafting
CALP h1-calponin
CDC cardiosphere-derived cell
CDS chondroitin sulfate
cGMP current good manufacturing practice
CM condition medium
CMP collagen mimetic oligopeptide
CNS central nervous system
BiomaterialsScienceSeriesNo.4
BiomaterialControlofTherapeuticStemCells
ByAkonHiguchi
rAkonHiguchi2019
PublishedbytheRoyalSocietyofChemistry,www.rsc.org
vii
View Online
viii Abbreviations
COL collagen
CS chitosan
CSC cardiac stem cell
CV conduction velocity
07 CXCR4 chemokine receptor type 4
0
FP DA cell dopaminergic cell
90- DE definitive endoderm
6
12 DEAEA 2-(diethylamino)ethyl acrylate
0
88 DMEM Dulbecco’s Modified Eagle’s Medium
7
81 DMSO dimethyl sulfoxide
7
9/9 DPS cell dental pulp stem cell
3
0 EB embryoid body
1
10. EC endothelial cell
doi: ECM extracellular matrix
g | EDC 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
or
c. EHS sarcoma cell Engelbreth–Holm–Swarm sarcoma cell
s
bs.r ELP elastin-like polypeptide
u
ps://p EERSKcell, ESC eemxtrbarcyeolnluiclasrtseimgncaelllregulated kinase
n htt ESV end-systolic volume
o
9 ETDRS early treatment diabetic retinopathy study
1
20 EV extracellular vesicles
y
ar EVAL poly(ethylene-co-vinyl alcohol)
u
br FA focal adhesion
e
F
8 FACS fluorescence activated cell sorting
1
n FAK focal adhesion kinase
o
ed FBS fetal bovine serum
h
blis FG fibrinogen
Pu FGF fibroblast growth factor
FISH fluorescence in situ hybridization
FN fibronectin
FOXA2 forkhead box A2
GABA inhibitory cell gamma-aminobutyric acid inhibitory cell
GAG glycosaminoglycan
G-CSF granulocyte colony-stimulating factor
GDNF glial cell-derived neurotrophic factor
GFAP glial fibrillary acidic protein
GMP good manufacturing practice
HA hyaluronic acid
H&E hematoxylin and eosin
HBP heparin-binding peptide
HUVEC human umbilical vein endothelial cell
HYA hyaluronic acid
hADS cell human adipose-derived stem cell
hAS cell human adult stem cell
hBMN cell human bone marrow mononuclear cell
View Online
Abbreviations ix
hBMS cell human bone marrow stem cell
hCNS-SC human central nervous system stem cell
hES cell, hESC human embryonic stem cells
hMS cell human mesenchymal stem cell
07 HNF1a hepatocyte nuclear factor 1 homeobox A
0
FP hiPS cell, hiPSC human induced pluripotent stem cell
90- hPS cell, hPSC human pluripotent stem cell
6
12 hWJ-MS cell human Wharton’s jelly-derived mesenchymal
0
88 stem cell
7
81 ICC inverted colloidal crystal
7
9/9 ICG indocyanine green
3
0 IgG immunoglobulin
1
10. ILK integrin-linked kinase
doi: INL inner nuclear layer
g | IPC insulin producing cell
or
c. IPL inner plexiform layer
s
bs.r IPN interpenetrating network
u
ps://p iKPSSRcell iknndoucckeodutpsluerriupmoterenptlsatceemmecneltl
n htt LCST low critical solution temperature
o
9 LDL low-density lipoprotein
1
20 LIF leukemia inhibitory factor
y
ar LLS linear local shortening
u
br LN laminin
e
F
8 LV left ventricular
1
n LVEDV left ventricular end-diastolic volume
o
ed LVEF left ventricular ejection fraction
h
blis LVESV left ventricular end-systolic volume
Pu MACS magnetic-activated cell sorting
MAPK mitogen-activated protein kinases
MARC chip multi-architecture chip
MC microcarrier
MCFU mesenchymal colony-forming unit
MEF-CMorMEFs-CM condition medium from MEF(s)
MEF2c myocyte enhancer factor 2C
MFB medial forebrain bundle
MI myocardial infarction
MLC-2a myosin light chain-2a
MMP matrix metalloproteinase
MRI magnetic resonance imaging
MS cell, MSC mesenchymal stem cell
mES cell mouse embryonic stem cell
NCM neonatal rat cardiomyocyte
NCSC neural crest stem cell
NHS N-hydroxysuccinimide
NPC neural progenitor cell
View Online
x Abbreviations
NPS cell neural progenitor/stem cell
NS cell neural stem cell
OCT optical coherence tomography
OmpA outer membrane protein A
07 ONL outer nuclear layer
0
FP PA oligopeptide amphiphile
90- PAAm, PAA polyacrylamide
6
12 PAS biologically active peptides
0
88 PBS phosphate buffered saline
7
81 PCBMA poly(carboxybetaine methacrylate)
7
9/9 PCI percutaneous coronary intervention
3
0 PCL poly(3-caprolactone)
1
10. PDDLA poly-DL-lactic acid
doi: PDL poly-D-lysine
g | PE polyethylene
or
c. PE cell pancreatic endoderm cell
s
bs.r PECM placenta-derived ECM scaffolds
u
ps://p PPEEGGDA ppoollyye(etthhyylelenneegglylyccooll) dimethacrylate
n htt PEODA poly(ethylene oxide) dimethacrylate
o
9 PET positron emission computed tomography or
1
20 poly(ethylene terephthalate)
y
ar PF posterior foregut
u
br PGA poly(glycolic acid)
e
F
8 PGT primitive gut tube
1
n PHA polyhydroxyalkanoate
o
ed PhaC PHA synthase
h
blis PhaP PHA granule-associated proteins
Pu PHBHHx poly(3-hydroxybutyrate-co-hydroxyhexanoate)
PHEMA poly(2-hydroxyethyl methacrylate)
PLCL poly(L-lactic acid)-co-poly(3-caprolactone)
PLGA poly(lactic-co-glycolic acid)
PLL poly-L-lysine
PMEDSAH poly(2-[methacryloyloxy]ethyldimethyl-[3-sulfopropyl]
ammoniumhydroxide)
PMVE-alt-MA poly(methylvinyl ether-alt-maleic anhydride)
PNIPAM poly(N-isopropylacrylamide)
PPEGMA poly(poly[ethylene glycol] methyl ether
methacrylate)
PMETAC poly([2-(methacryloyloxy)ethyl])
PPS phosphatidylserine
PROD pentoxyresorufin o-dealkylase activity
PS polystyrene
PSC, PS cell pluripotent stem cell
PSPMA poly(3-sulfopropyl methacrylate)
PVA polyvinyl alcohol